CN114606345A - 一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒 - Google Patents

一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒 Download PDF

Info

Publication number
CN114606345A
CN114606345A CN202210056150.9A CN202210056150A CN114606345A CN 114606345 A CN114606345 A CN 114606345A CN 202210056150 A CN202210056150 A CN 202210056150A CN 114606345 A CN114606345 A CN 114606345A
Authority
CN
China
Prior art keywords
leu
gly
ser
ala
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202210056150.9A
Other languages
English (en)
Other versions
CN114606345B (zh
Inventor
陈鹏
杨洪军
崔钊
黎彩凤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Original Assignee
EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES filed Critical EXPERIMENTAL RESEARCH CENTER CHINA ACADEMY OF CHINESE MEDICAL SCIENCES
Priority to CN202210056150.9A priority Critical patent/CN114606345B/zh
Publication of CN114606345A publication Critical patent/CN114606345A/zh
Application granted granted Critical
Publication of CN114606345B publication Critical patent/CN114606345B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701Specific hybridization probes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6851Quantitative amplification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

本发明提供了一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒,用于筛选作用于新型冠状病毒(新冠病毒)靶点蛋白的药物和临床有效药物的作用靶点筛选。所述的蛋白质芯片热稳定性检测中包括新冠病毒的潜在靶点蛋白的种类包括:重组人蛋白ACE2、Cathepsin B(CTSB)、CD147、AXL、Anneixn A2、HMGB1、NFκB1(P50)、MAPK1、TAB1、重组病毒蛋白SARS‑CoV‑2Nucleocapsid Protein、Non‑structural protein SARS‑CoV‑2 NSP2、SARS‑CoV‑2 3C‑like Proteinase,所述试剂盒还包括:样品稀释液、对照品等。本发明试剂盒填补行业空白,解决现实需求,具有通量高、简便快捷、无需标记、产品稳定的特点,数据真实可靠,对新冠病毒科研可能起到推动作用。

Description

一种蛋白质热稳定性检测芯片的制备方法、检测方法和试 剂盒
技术领域
本发明属于生物医药技术领域,具体涉及一种新型冠状病毒药物靶点蛋白质稳定性高通量检测芯片以及试剂盒。
背景技术
蛋白质参与疾病的发生和发展过程,可以作为疾病靶标来开发特异性药物起到治疗的效果。以蛋白质作为药物靶点的药物筛选方法有很多种,例如基于SP R(SurfacePlasmon Resonance)技术、等温滴定量热技术ITC(Isothermal titra tion calorimetry)等,但是这些方法也存在缺点。首先,检测通量低,每次(批) 只能检测少数样本;其次,仪器设备造价高,属于专用设备,不具有通用性。
中药具有组方快,副作用小的特点,在面对新型冠状病毒早期可以快速应用救治患者。中药具有先临床应用后药理研究的特点,目前一些疗效确切的中药和天然产物缺乏相关的靶点研究工具。
现有技术中目前没有直接检测蛋白质与药物相互作用且可以实时检测的基于蛋白热稳定性原理的蛋白质芯片,也没有针对新型冠状病毒的药物靶点作用分子筛选的蛋白质芯片和试剂盒。研究与开发新的使用方便、高通量、可实时监测的检测蛋白质与药物分子相互作用的方法和产品,是解决上述问题的关键。
发明内容
为了解决上述问题,本发明提供了一种基于蛋白质热稳定性的蛋白质芯片并进行了条件优化和针对新冠病毒靶点的试剂盒建立,可以实现在常规PCR仪器上实现高通量非标记的新冠病毒靶点药物筛选。
本发明基于蛋白质热稳定性,利用蛋白质热转移分析去开发新的高通量检测产品和试剂盒。分子(此处包含蛋白、抗体、小分子药物、中药复杂成分体系) 与蛋白发生相互作用时,蛋白质的构象大多会发生变化,进而其稳定性就会发生改变。蛋白质热转移分析是基于蛋白质结构的疏水性部位随着温度的上升,逐渐暴露出来的原理,通过荧光素与蛋白质疏水性部分的结合,以荧光量随温度上升而变化的曲线形式,揭示特定蛋白质在稳定性上的特性。目前针对蛋白热稳定性检测的产品和技术都是单通道的,尚没有实现高通量的检测,疾病的治疗靶点往往是众多的,这使得该方法无法进行多靶点的高通量的药物筛选和未知靶点药物的靶点筛选。
基于上述问题和科学原理,本专利首次提出一种结合蛋白质热稳定性分析和生物芯片原理的筛选新型冠状病毒药物靶点相关分子的蛋白质热稳定性检测芯片和试剂盒。常规的蛋白质热稳定性是单通道的,据蛋白靶点与药物反应前后热稳定曲线的变化差异,可以判断蛋白是否与药物存在相互作用。本试剂盒新创、优化了制备和检测条件,提高了新冠病毒相关蛋白靶点热稳定性检测的速度和通量。
一方面,本发明提供了一种蛋白质热稳定性检测芯片。
所述的蛋白质热稳定性检测芯片为高通量靶点蛋白质热稳定性检测芯片。
所述的蛋白质热稳定性检测芯片用于筛选作用于新冠病毒靶点蛋白的药物和未知靶点药物的靶点筛选。
所述的蛋白质热稳定性检测芯片中包括新冠病毒的潜在靶点蛋白的纯品。
所述的靶点蛋白包括经过网络药理学筛选相关的高频药物靶点,包含宿主来源和病毒来源两部分。
所述的靶点蛋白的种类至少包括:重组人蛋白ACE2、Cathepsin B(CTSB)、 CD147、AXL、Anneixn A2、HMGB1、NFκB1(P50)、MAPK1、TAB1、重组病毒SARS-CoV-2 NucleocapsidProtein、Non-structural protein SARS-CoV-2 NSP2、SARS-CoV-2 3C-like Proteinase。
优选地,所述的靶点蛋白的种类包括:重组人蛋白ACE2、Cathepsin B (CTSB)、CD147、AXL、Anneixn A2、HMGB1、NFκB1-P50、MAPK1、TAB1、重组病毒SARS-CoV-2Nucleocapsid Protein、Non-structural protein SARS-CoV-2 NSP2、SARS-CoV-2 3C-like Proteinase。
进一步优选地,所述的靶点蛋白用于热稳定性检测的序列为SEQ ID NO.1-12。
优选地,所述的蛋白质热稳定性检测芯片用于热稳定性检测NFκB1(P50) 蛋白工作浓度为0.02-1μg/μL;进一步优选为0.045μg/μL。
优选地,所述的ACE2、Cathepsin B(CTSB)、CD147、AXL、Anneixn A2、 HMGB1、NFκB1(P50)、MAPK1、TAB1、重组病毒SARS-CoV-2 Nucleocapsid Protein、Non-structuralprotein SARS-CoV-2 NSP2、SARS-CoV-2 3C-like Proteinase 用于热稳定性检测的工作浓度分别为0.045-1μg/μL;进一步优选为0.09μg/μL。
所述的靶点蛋白用于热稳定性检测的纯度为90%及以上。
所述的靶点蛋白保存在保存液中,所述的保存液含有10-30%甘油, pH=6.7-7.5的磷酸盐缓冲液;所述的保存液中还包括防腐剂和信号增强剂。
优选地,所述的保存液含有20%甘油,pH=7的磷酸盐缓冲液。
所述的信号增强剂为0.001-0.1%叠氮化钠;优选为0.01%的叠氮化钠。
所述的芯片的载体为反应板,所述的靶点蛋白分布在反应板上。
所述的反应板为不含荧光成分的聚丙烯塑料多孔反应板。
所述的反应板中每孔含有对应的靶点蛋白体积10μL,浓度为蛋白工作浓度的2倍。
所述的蛋白质热稳定性检测芯片制备方法,不同于常规蛋白质芯片的制备方法,该芯片采用聚丙烯塑料多孔板为基片,每个孔为独立的蛋白检测点,采用自动化液体工作站进行批量生产。
所述的蛋白质热稳定性检测芯片可长期保存在4℃。
所述的蛋白质热稳定性检测芯片可用于检测蛋白、抗体、小分子以及小分子混合物。
另一方面,本发明提供了一种用于筛选新型冠状病毒靶点药物的试剂盒。
所述的试剂盒中包括前述的蛋白质热稳定性检测芯片。
所述的试剂盒中还包括:样品稀释液、荧光染料、质控品、阳性对照品和阴性对照品。
所述的样品稀释液为含有10-30%甘油,pH=6.7-7.5的磷酸盐缓冲液;所述的保存液中还包括防腐剂和信号增强剂。
优选地,所述的样品稀释液为含有20%甘油,pH=7的磷酸盐缓冲液。
优选的,所述的荧光染料为5μM的SYPRO Orange。
优选的,信号增强剂为质量浓度0.01%的叠氮化钠,同时叠氮化钠具备防腐剂的双重功能。
所述的质控品为阳性对照和阴性对照组成。
所述的阳性对照品为大分子为0.1μg/μL的新冠病毒N蛋白抗体(购买自上海近岸蛋白有限公司,货号DA042)以及100μM的绿原酸单体。
所述的阴性对照品为不含药物的0.01M磷酸盐,质量浓度0.01%的叠氮化钠缓冲液。
所述的试剂盒可用于有效中药复杂成分的抗新冠病毒作用靶点的直接筛选,其检测方法特征在于中药混合物复杂成分无需标记和分离,中药复杂成分检测经超滤去除蛋白,以靶点蛋白的热稳定性Tm数值变化判断是否为中药的靶点。
再一方面,本发明提供了前述试剂盒的使用方法。
包括以下步骤:
(1)制备好的芯片从低温取出至室温、复温30min;
(2)准备稀释好的药物样品(10μM),抗体浓度为0.1μg/μL,中药混合体系稀释比小于1:10,总体积为10μL;
(3)将相应的反应板或试管放在冰上,将稀释好的药物加入反应板,反应体系(20μL);
(4)每次反应用移液器(或者自动化加样设备)上下吹吸10次,搅拌均匀;
(5)用无荧光光学胶膜密封板,以1000转/分旋转1分钟后,上PCR仪检测,采用荧光定量PCR仪器,特征参数为37-99℃,每0.3℃测一次荧光强度(报告荧光设置成SYPROorange染料相对应的参数);
(6)热稳定曲线的数据处理方法,其特征为从PCR仪上导出温度和对应的荧光信号强度,采用作图软件做出样品和对照的蛋白靶点的熔解曲线(温度变化曲线),标注出两组荧光强度最高点对应的温度TmX(样品)和对照组TmC(对照),ΔTm=TmX-TmC,四个重复孔取平均值;
(7)本发明可与自动化液体工作站、机器人设备联用,可形成快速高通量的药物和靶点筛选平台。
本发明的有益效果:
本发明采用荧光定量PCR与蛋白质芯片理论结合研制出蛋白质热稳定性检测芯片,应用于蛋白质结合的检测中有着通量高、简便快捷、无需标记,实时监控,产品稳定,数据真实可靠的优点,也能同时进行多样本的同时检测,适合推广应用以及联合自动化平台使用,该试剂盒用于筛选新冠靶点蛋白的结合的药物和临床有效药物靶点的筛选,可能有助于新冠的疫情防治和科研。
附图说明
图1为蛋白热稳定性检测芯片的原理和应用示意图。
图2为蛋白热稳定性检测芯片所用的蛋白种类分布和芯片设计图。
图3为蛋白热稳定性检测芯片试剂盒的优选的荧光增强剂结果。
图4为蛋白质芯片上所有蛋白的热稳定曲线部分质控结果。
图5为蛋白质芯片上所有蛋白的热稳定曲线部分质控结果。
图6为小分子药物靶点筛选实验测试结果,An:annexin A2蛋白;CLA:绿原酸。
图7为大分子药物靶点筛选实验测试结果,Nucleocapsid(Nucl):新冠病毒N蛋白;Anti-Nucleocapsid:新冠病毒N蛋白抗体。
图8为中药复方药物靶点筛选实验测试结果,Pinellia ternate:半夏水提取物。
具体实施方式
下面结合具体实施例,对本发明作进一步详细的阐述,下述实施例不用于限制本发明,仅用于说明本发明。以下实施例中所使用的实验方法如无特殊说明,实施例中未注明具体条件的实验方法,通常按照常规条件,下述实施例中所使用的材料、试剂等,如无特殊说明,均可从商业途径得到。
实施例1一种新型冠状病毒药物靶点蛋白质热稳定性检测芯片
本实施例的蛋白质稳定性检测芯片原理和应用示意见图1。
该特制蛋白质热稳定性检测芯片和试剂盒,在孔板中含有新冠病毒的靶点蛋白的纯品,药物分子用样品稀释液稀释好后加入到反应板的不同区域。
样品稀释液为:pH=7.0的0.01M磷酸盐缓冲液(经过无菌过滤),以及0.01%的叠氮化钠信号增强剂。
采用荧光的定量PCR仪器固定参数进行测量,获得靶点蛋白在有无药物分子情况下的热稳定性曲线,采用本试剂盒的判断是否发生分子相互作用。
蛋白质热稳定性检测芯片所用的蛋白种类分布和芯片设计图见图2。
反应板上同时固定了多种新冠病毒靶点蛋白,靶点蛋白的种类包括:重组人蛋白ACE2、Cathepsin B(CTSB)、CD147、AXL、Anneixn A2、HMGB1、NFκB1-P50、MAPK1、TAB1、重组病毒SARS-CoV-2 Nucleocapsid Protein、 Non-structural protein SARS-CoV-2 NSP2、SARS-CoV-2 3C-like Proteinase共12 个相关蛋白质。保存在4℃。
靶点蛋白在大肠杆菌中表达、分离、纯化,得到以上12种特征氨基酸序列 (SEQ IDNO.1-12)的重组蛋白,纯度要求达到90%以上。
蛋白表达纯化方法如下:
蛋白质粒表达采用Pet28a质粒,抗性为Kana抗性,BL21(DE3)为表达菌种;
质粒转化到菌种后,不直接进行扩增,而是在经过两轮含有Kana抗性的平板上进行单克隆筛选,其具体操作方法为平板稀释划线法。以获得高纯度的单克隆菌株;
菌种的扩增程序首先采用1:100的体积比接种到5mL的LB培养基中(Kana 抗性,0.05mg/mL),37℃,170rpm摇菌12小时,再以1:100的体积比接种到500mL LB培养基中(Kana抗性,0.05mg/mL),37℃,170rpm摇菌12小时待菌生长至平台期后再进行IPTG诱导,诱导条件的为16℃,170rpm,12小时。
菌的收集和破碎流程:菌体离心4000rpm,20min,收集菌体,超声破碎(3s 破碎,1s间歇,50次,超声功率50%)。破碎缓冲液为0.1M的pH=7.0的磷酸盐,5mL,离心12000rpm,10min,取上清。
采用琼脂糖镍填料的重力柱进行纯化,上柱三次,优化后的洗涤条件为100 mL20mM咪唑洗杂蛋白,洗脱条件1mL 200mM咪唑。
芯片的制备流程:采用自动化工作站,按照芯片的设计图,将10μL含有不同靶蛋白终浓度2倍的保存液依次等体积加样,加样完成后进行膜封,放入4℃保存。
实施例2一种用于筛选新冠病毒靶点药物的试剂盒
包括:实施例1中的蛋白质热稳定性检测芯片、样品稀释液、阳性对照品和阴性对照品。
样品稀释液为:pH=7.0的0.01M磷酸盐缓冲液(经过无菌过滤),以及0.01%叠氮化钠作为的信号增强剂和防腐剂,5μM的荧光染料。
本试剂盒在前期研发过程中,发现荧光信号浓度不强,而使用高浓度蛋白又会带来成本增加问题,另外小分子药物有的也具有自发荧光,会带来较高的背景,同时试剂盒的长期保存也需要防腐剂,为了以上解决以上问题,我们测试了多种化学分子添加剂,并对他们的性能做了测试,测试结果如图3所示。结果表明添加0.01%叠氮化钠能够显著提高检测信号,且不对蛋白热稳定性产生影响,不会带来误差。图3中,Buffer 1:纯水;Buffer 2:0.01M磷酸盐缓冲液;Buffer 3: 0.01M磷酸盐缓冲液+1.5%海藻糖;Buffer 4:0.01M磷酸盐缓冲液+1.5%海藻糖 +0.1%5-氯-2-甲基-4-异噻唑啉-3-酮(5-chloro-2-methyl-4-isothiazolin-3-one,CMIT) 和2-甲基-4-异噻唑啉-3-酮(2-methyl-4-isothiazloin-3-one,MIT)的质量比3:1混合物;Buffer 5:0.01M磷酸盐缓冲液+0.01%叠氮化钠。根据测试结果,Buffer 5 具有增强荧光信号强度的功能,且不影响蛋白Tm值。
荧光染料为的SYPRO Orange。
阳性对照品为大分子为新冠病毒N蛋白的抗体(购买自上海近岸蛋白有限公司,货号DA042),浓度为1μg/μL;小分子对照为绿原酸标准药品,浓度为100μM。
将以上组分进行组装,试剂盒放入4℃保存。
实施例3靶点蛋白质标准热稳定曲线质控
对实施例1中制备的蛋白进行标准热稳定曲线质控,将10μL蛋白样品稀释液加入到各蛋白的反应孔中,终体积20μL。
启动程序:
该蛋白质芯片所有蛋白的质控图如图4、图5所示,每种蛋白在不加药物时的正常熔解曲线,其中(NFkB1)P50蛋白进行了四个蛋白浓度的摸索,根据试剂盒蛋白浓度摸索条件测试结果,本试剂盒采用NFκB1(P50)蛋白终浓度在 0.045μg/μL,本试剂盒其他蛋白选择浓度为0.09μg/μL蛋白浓度进行实验。
上机检测的程序如下:
启动程序:
步骤1,温度37℃,时间2分钟;
变温程序:
步骤1:1.0℃/s,37-60℃;
步骤2:0.5℃/s,60-90℃;
结束后,在仪器上读取实时荧光定量PCR的扩增曲线和熔解曲线,导出温度和荧光信号对应的数值,用软件绘制出曲线图,以曲线峰值对应的温度为Tm 值,并用软件分析。
实施例4该产品用于新冠靶点小分子的药物的结合测试结果
针对实施例2制备的试剂盒,按照如下加样量配制反应体系:
向芯片的体系中加入用样品稀释液稀释的小分子药物绿原酸,终浓度10μ M,药物稀释比小于1:10;
上机检测的程序进行设置,如下所示:
启动程序:
步骤1,温度37℃,时间2分钟;
变温程序:
步骤1:1.0℃/s,37-60℃;
步骤2:0.5℃/s,60-90℃;
结束后,在仪器上读取实时荧光定量PCR的扩增曲线和熔解曲线,导出温度和荧光信号对应的数值,用软件绘制出曲线图,以曲线峰值对应的温度为Tm 值,并用软件分析,计算ΔTm值。
小分子药物筛选实验如图6所示,为annexin a2与结合药物绿原酸的靶点,通过已知的药物和靶点结合的情况对该试剂盒进行阳性测试,表明该试剂盒能够在小分子药物筛选领域工作。
实施例5该产品用于新冠靶点大分子药物的结合测试结果
针对实施例2制备的试剂盒,用样品稀释液向芯片的体系中加入新冠病毒N 蛋白的抗体(购买自上海近岸蛋白有限公司,货号DA042)质量2μg,具体操作步骤如下:
上机检测的程序如下:
启动程序:
步骤1,温度37℃,时间2分钟;
变温程序:
步骤1:1.0℃/s,37-60℃;
步骤2:0.5℃/s,60-90℃;
结束后,在仪器上读取实时荧光定量PCR的扩增曲线和熔解曲线,并按照实施例4方法用软件分析,计算ΔTm值。
大分子药物筛选实验如图7所示,用已知的新冠病毒N蛋白抗体去测试大分子抗体药物对N蛋白的影响,结果N蛋白的ΔTm值出现明显转移。
实施例6该产品用于复杂中药体系的靶点筛选
针对实施案例2中的试剂盒,首先对中药复杂体系(此处为半夏的水提物,原药浓度1.00g/mL,药材购买自北京同仁堂股份集团)进行去大分子处理,采用3kDa的超滤管4℃离心,30min,去除其中的大分子带来的干扰;按照1: 10采用样本稀释液对中药复杂体系进行稀释,具体操作步骤如下:
上机检测的程序如下:
启动程序:
步骤1,温度37℃,时间2分钟;
变温程序:
步骤1:1.0℃/s,37-60℃;
步骤2:0.5℃/s,60-90℃;
结束后,计算ΔTm值。
中药药物靶点筛选实验如图8所示,结果表明半夏对ACE-2蛋白的ΔTm值出现明显转移。
实施例7试剂盒的准确度
针对实施例2中的实际盒,参照实施例5的方法,对新冠病毒N蛋白的抗体进行10次重复检测,并设置空白对照,结果表明,10次检测均出现与实施例 5相同的结果,空白对照均无结果,本试剂盒的重复率和准确率较高。
实施例8试剂盒的灵敏度
参照实施例4的实验方法,对绿原酸进行浓度梯度稀释后检测,结果表明本发明的对绿原酸的最低检测限为0.5μM,试剂盒操作所要求的10μM浓度,完全保证小分子与靶点蛋白的真实结合能够被检出。
序列表
<110> 中国中医科学院医学实验中心
<120>一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒
<160> 12
<170> SIPOSequenceListing 1.0
<210> 1
<211> 800
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Met Ser Ser Ser Ser Trp Leu Leu Leu Ser Leu Val Ala Val Thr Ala
1 5 10 15
Ala Gln Ser Thr Ile Glu Glu Gln Ala Lys Thr Phe Leu Asp Lys Phe
20 25 30
Asn His Glu Ala Glu Asp Leu Phe Tyr Gln Ser Ser Leu Ala Ser Trp
35 40 45
Asn Tyr Asn Thr Asn Ile Thr Glu Glu Asn Val Gln Asn Met Asn Asn
50 55 60
Ala Gly Asp Lys Trp Ser Ala Phe Leu Lys Glu Gln Ser Thr Leu Ala
65 70 75 80
Gln Met Tyr Pro Leu Gln Glu Ile Gln Asn Leu Thr Val Lys Leu Gln
85 90 95
Leu Gln Ala Leu Gln Gln Asn Gly Ser Ser Val Leu Ser Glu Asp Lys
100 105 110
Ser Lys Arg Leu Asn Thr Ile Leu Asn Thr Met Ser Thr Ile Tyr Ser
115 120 125
Thr Gly Lys Val Cys Asn Pro Asp Asn Pro Gln Glu Cys Leu Leu Leu
130 135 140
Glu Pro Gly Leu Asn Glu Ile Met Ala Asn Ser Leu Asp Tyr Asn Glu
145 150 155 160
Arg Leu Trp Ala Trp Glu Ser Trp Arg Ser Glu Val Gly Lys Gln Leu
165 170 175
Arg Pro Leu Tyr Glu Glu Tyr Val Val Leu Lys Asn Glu Met Ala Arg
180 185 190
Ala Asn His Tyr Glu Asp Tyr Gly Asp Tyr Trp Arg Gly Asp Tyr Glu
195 200 205
Val Asn Gly Val Asp Gly Tyr Asp Tyr Ser Arg Gly Gln Leu Ile Glu
210 215 220
Asp Val Glu His Thr Phe Glu Glu Ile Lys Pro Leu Tyr Glu His Leu
225 230 235 240
His Ala Tyr Val Arg Ala Lys Leu Met Asn Ala Tyr Pro Ser Tyr Ile
245 250 255
Ser Pro Ile Gly Cys Leu Pro Ala His Leu Leu Gly Asp Met Trp Gly
260 265 270
Arg Phe Trp Thr Asn Leu Tyr Ser Leu Thr Val Pro Phe Gly Gln Lys
275 280 285
Pro Asn Ile Asp Val Thr Asp Ala Met Val Asp Gln Ala Trp Asp Ala
290 295 300
Gln Arg Ile Phe Lys Glu Ala Glu Lys Phe Phe Val Ser Val Gly Leu
305 310 315 320
Pro Asn Met Thr Gln Gly Phe Trp Glu Asn Ser Met Leu Thr Asp Pro
325 330 335
Gly Asn Val Gln Lys Ala Val Cys His Pro Thr Ala Trp Asp Leu Gly
340 345 350
Lys Gly Asp Phe Arg Ile Leu Met Cys Thr Lys Val Thr Met Asp Asp
355 360 365
Phe Leu Thr Ala His His Glu Met Gly His Ile Gln Tyr Asp Met Ala
370 375 380
Tyr Ala Ala Gln Pro Phe Leu Leu Arg Asn Gly Ala Asn Glu Gly Phe
385 390 395 400
His Glu Ala Val Gly Glu Ile Met Ser Leu Ser Ala Ala Thr Pro Lys
405 410 415
His Leu Lys Ser Ile Gly Leu Leu Ser Pro Asp Phe Gln Glu Asp Asn
420 425 430
Glu Thr Glu Ile Asn Phe Leu Leu Lys Gln Ala Leu Thr Ile Val Gly
435 440 445
Thr Leu Pro Phe Thr Tyr Met Leu Glu Lys Trp Arg Trp Met Val Phe
450 455 460
Lys Gly Glu Ile Pro Lys Asp Gln Trp Met Lys Lys Trp Trp Glu Met
465 470 475 480
Lys Arg Glu Ile Val Gly Val Val Glu Pro Val Pro His Asp Glu Thr
485 490 495
Tyr Cys Asp Pro Ala Ser Leu Phe His Val Ser Asn Asp Tyr Ser Phe
500 505 510
Ile Arg Tyr Tyr Thr Arg Thr Leu Tyr Gln Phe Gln Phe Gln Glu Ala
515 520 525
Leu Cys Gln Ala Ala Lys His Glu Gly Pro Leu His Lys Cys Asp Ile
530 535 540
Ser Asn Ser Thr Glu Ala Gly Gln Lys Leu Phe Asn Met Leu Arg Leu
545 550 555 560
Gly Lys Ser Glu Pro Trp Thr Leu Ala Leu Glu Asn Val Val Gly Ala
565 570 575
Lys Asn Met Asn Val Arg Pro Leu Leu Asn Tyr Phe Glu Pro Leu Phe
580 585 590
Thr Trp Leu Lys Asp Gln Asn Lys Asn Ser Phe Val Gly Trp Ser Thr
595 600 605
Asp Trp Ser Pro Tyr Ala Asp Gln Ser Ile Lys Val Arg Ile Ser Leu
610 615 620
Lys Ser Ala Leu Gly Asp Lys Ala Tyr Glu Trp Asn Asp Asn Glu Met
625 630 635 640
Tyr Leu Phe Arg Ser Ser Val Ala Tyr Ala Met Arg Gln Tyr Phe Leu
645 650 655
Lys Val Lys Asn Gln Met Ile Leu Phe Gly Glu Glu Asp Val Arg Val
660 665 670
Ala Asn Leu Lys Pro Arg Ile Ser Phe Asn Phe Phe Val Thr Ala Pro
675 680 685
Lys Asn Val Ser Asp Ile Ile Pro Arg Thr Glu Val Glu Lys Ala Ile
690 695 700
Arg Met Ser Arg Ser Arg Ile Asn Asp Ala Phe Arg Leu Asn Asp Asn
705 710 715 720
Ser Leu Glu Phe Leu Gly Ile Gln Pro Thr Leu Gly Pro Pro Asn Gln
725 730 735
Pro Pro Val Ser Ile Trp Leu Ile Val Phe Gly Val Val Met Gly Val
740 745 750
Ile Val Val Gly Ile Val Ile Leu Ile Phe Thr Gly Ile Arg Asp Arg
755 760 765
Lys Lys Lys Asn Lys Ala Arg Ser Gly Glu Asn Pro Tyr Ala Ser Ile
770 775 780
Asp Ile Ser Lys Gly Glu Asn Asn Pro Gly Phe Gln Asn Thr Asp Asp
785 790 795 800
<210> 2
<211> 320
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Trp Gln Leu Trp Ala Ser Leu Cys Cys Leu Leu Val Leu Ala Asn
1 5 10 15
Ala Arg Ser Arg Pro Ser Phe His Pro Leu Ser Asp Glu Leu Val Asn
20 25 30
Tyr Val Asn Lys Arg Asn Thr Thr Trp Gln Ala Gly His Asn Phe Tyr
35 40 45
Asn Val Asp Met Ser Tyr Leu Lys Arg Leu Cys Gly Thr Phe Leu Gly
50 55 60
Gly Pro Lys Pro Pro Gln Arg Val Met Phe Thr Glu Asp Leu Lys Leu
65 70 75 80
Pro Ala Ser Phe Asp Ala Arg Glu Gln Trp Pro Gln Cys Pro Thr Ile
85 90 95
Lys Glu Ile Arg Asp Gln Gly Ser Cys Gly Ser Cys Trp Ala Phe Gly
100 105 110
Ala Val Glu Ala Ile Ser Asp Arg Ile Cys Ile His Thr Asn Ala His
115 120 125
Val Ser Val Glu Val Ser Ala Glu Asp Leu Leu Thr Cys Cys Gly Ser
130 135 140
Met Cys Gly Asp Gly Cys Asn Gly Gly Tyr Pro Ala Glu Ala Trp Asn
145 150 155 160
Phe Trp Thr Arg Lys Gly Leu Val Ser Gly Gly Leu Tyr Glu Ser His
165 170 175
Val Gly Cys Arg Pro Tyr Ser Ile Pro Pro Cys Glu His His Val Asn
180 185 190
Gly Ser Arg Pro Pro Cys Thr Gly Glu Gly Asp Thr Pro Lys Cys Ser
195 200 205
Lys Ile Cys Glu Pro Gly Tyr Ser Pro Thr Tyr Lys Gln Asp Lys His
210 215 220
Tyr Gly Tyr Asn Ser Tyr Ser Val Ser Asn Ser Glu Lys Asp Ile Met
225 230 235 240
Ala Glu Ile Tyr Lys Asn Gly Pro Val Glu Gly Ala Phe Ser Val Tyr
245 250 255
Ser Asp Phe Leu Leu Tyr Lys Ser Gly Val Tyr Gln His Val Thr Gly
260 265 270
Glu Met Met Gly Gly His Ala Ile Arg Ile Leu Gly Trp Gly Val Glu
275 280 285
Asn Gly Thr Pro Tyr Trp Leu Val Ala Asn Ser Trp Asn Thr Asp Trp
290 295 300
Gly Asp Asn Gly Phe Phe Lys Ile Leu Arg Gly Gln Asp His Cys Gly
305 310 315 320
<210> 3
<211> 380
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Met Ala Ala Ala Leu Phe Val Leu Leu Gly Phe Ala Leu Leu Gly Thr
1 5 10 15
His Gly Ala Ser Gly Ala Ala Gly Phe Val Gln Ala Pro Leu Ser Gln
20 25 30
Gln Arg Trp Val Gly Gly Ser Val Glu Leu His Cys Glu Ala Val Gly
35 40 45
Ser Pro Val Pro Glu Ile Gln Trp Trp Phe Glu Gly Gln Gly Pro Asn
50 55 60
Asp Thr Cys Ser Gln Leu Trp Asp Gly Ala Arg Leu Asp Arg Val His
65 70 75 80
Ile His Ala Thr Tyr His Gln His Ala Ala Ser Thr Ile Ser Ile Asp
85 90 95
Thr Leu Val Glu Glu Asp Thr Gly Thr Tyr Glu Cys Arg Ala Ser Asn
100 105 110
Asp Pro Asp Arg Asn His Leu Thr Arg Ala Pro Arg Val Lys Trp Val
115 120 125
Arg Ala Gln Ala Val Val Leu Val Leu Glu Pro Gly Thr Val Phe Thr
130 135 140
Thr Val Glu Asp Leu Gly Ser Lys Ile Leu Leu Thr Cys Ser Leu Asn
145 150 155 160
Asp Ser Ala Thr Glu Val Thr Gly His Arg Trp Leu Lys Gly Gly Val
165 170 175
Val Leu Lys Glu Asp Ala Leu Pro Gly Gln Lys Thr Glu Phe Lys Val
180 185 190
Asp Ser Asp Asp Gln Trp Gly Glu Tyr Ser Cys Val Phe Leu Pro Glu
195 200 205
Pro Met Gly Thr Ala Asn Ile Gln Leu His Gly Pro Pro Arg Val Lys
210 215 220
Ala Val Lys Ser Ser Glu His Ile Asn Glu Gly Glu Thr Ala Met Leu
225 230 235 240
Val Cys Lys Ser Glu Ser Val Pro Pro Val Thr Asp Trp Ala Trp Tyr
245 250 255
Lys Ile Thr Asp Ser Glu Asp Lys Ala Leu Met Asn Gly Ser Glu Ser
260 265 270
Arg Phe Phe Val Ser Ser Ser Gln Gly Arg Ser Glu Leu His Ile Glu
275 280 285
Asn Leu Asn Met Glu Ala Asp Pro Gly Gln Tyr Arg Cys Asn Gly Thr
290 295 300
Ser Ser Lys Gly Ser Asp Gln Ala Ile Ile Thr Leu Arg Val Arg Ser
305 310 315 320
His Leu Ala Ala Leu Trp Pro Phe Leu Gly Ile Val Ala Glu Val Leu
325 330 335
Val Leu Val Thr Ile Ile Phe Ile Tyr Glu Lys Arg Arg Lys Pro Glu
340 345 350
Asp Val Leu Asp Asp Asp Asp Ala Gly Ser Ala Pro Leu Lys Ser Ser
355 360 365
Gly Gln His Gln Asn Asp Lys Gly Lys Asn Val Arg
370 375 380
<210> 4
<211> 860
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Val Pro Leu Ala Trp Cys Leu Ala Leu Cys Gly Trp Ala Cys Met Ala
1 5 10 15
Pro Arg Gly Thr Gln Ala Glu Glu Ser Pro Phe Val Gly Asn Pro Gly
20 25 30
Asn Ile Thr Gly Ala Arg Gly Leu Thr Gly Thr Leu Arg Cys Gln Leu
35 40 45
Gln Val Gln Gly Glu Pro Pro Glu Val His Trp Leu Arg Asp Gly Gln
50 55 60
Ile Leu Glu Leu Ala Asp Ser Thr Gln Thr Gln Val Pro Leu Gly Glu
65 70 75 80
Asp Glu Gln Asp Asp Trp Ile Val Val Ser Gln Leu Arg Ile Thr Ser
85 90 95
Leu Gln Leu Ser Asp Thr Gly Gln Tyr Gln Cys Leu Val Phe Leu Gly
100 105 110
His Gln Thr Phe Val Ser Gln Pro Gly Tyr Val Gly Leu Glu Gly Leu
115 120 125
Pro Tyr Phe Leu Glu Glu Pro Glu Asp Arg Thr Val Ala Ala Asn Thr
130 135 140
Pro Phe Asn Leu Ser Cys Gln Ala Gln Gly Pro Pro Glu Pro Val Asp
145 150 155 160
Leu Leu Trp Leu Gln Asp Ala Val Pro Leu Ala Thr Ala Pro Gly His
165 170 175
Gly Pro Gln Arg Ser Leu His Val Pro Gly Leu Asn Lys Thr Ser Ser
180 185 190
Phe Ser Cys Glu Ala His Asn Ala Lys Gly Val Thr Thr Ser Arg Thr
195 200 205
Ala Thr Ile Thr Val Leu Pro Gln Gln Pro Arg Asn Leu His Leu Val
210 215 220
Ser Arg Gln Pro Thr Glu Leu Glu Val Ala Trp Thr Pro Gly Leu Ser
225 230 235 240
Gly Ile Tyr Pro Leu Thr His Cys Thr Leu Gln Ala Val Leu Ser Asp
245 250 255
Asp Gly Met Gly Ile Gln Ala Gly Glu Pro Asp Pro Pro Glu Glu Pro
260 265 270
Leu Thr Ser Gln Ala Ser Val Pro Pro His Gln Leu Arg Leu Gly Ser
275 280 285
Leu His Pro His Thr Pro Tyr His Ile Arg Val Ala Cys Thr Ser Ser
290 295 300
Gln Gly Pro Ser Ser Trp Thr His Trp Leu Pro Val Glu Thr Pro Glu
305 310 315 320
Gly Val Pro Leu Gly Pro Pro Lys Asn Ile Ser Ala Thr Arg Asn Gly
325 330 335
Ser Gln Ala Phe Val His Trp Gln Glu Pro Arg Ala Pro Leu Gln Gly
340 345 350
Thr Leu Leu Gly Tyr Arg Leu Ala Tyr Gln Gly Gln Asp Thr Pro Glu
355 360 365
Val Leu Met Asp Ile Gly Leu Arg Gln Glu Val Thr Leu Glu Leu Gln
370 375 380
Gly Asp Gly Ser Val Ser Asn Leu Thr Val Cys Val Ala Ala Tyr Thr
385 390 395 400
Ala Ala Gly Asp Gly Pro Trp Ser Leu Pro Val Pro Leu Glu Ala Trp
405 410 415
Arg Pro Val Lys Glu Pro Ser Thr Pro Ala Phe Ser Trp Pro Trp Trp
420 425 430
Tyr Val Leu Leu Gly Ala Val Val Ala Ala Ala Cys Val Leu Ile Leu
435 440 445
Ala Leu Phe Leu Val His Arg Arg Lys Lys Glu Thr Arg Tyr Gly Glu
450 455 460
Val Phe Glu Pro Thr Val Glu Arg Gly Glu Leu Val Val Arg Tyr Arg
465 470 475 480
Val Arg Lys Ser Tyr Ser Arg Arg Thr Thr Glu Ala Thr Leu Asn Ser
485 490 495
Leu Gly Ile Ser Glu Glu Leu Lys Glu Lys Leu Arg Asp Val Met Val
500 505 510
Asp Arg His Lys Val Ala Leu Gly Lys Thr Leu Gly Glu Gly Glu Phe
515 520 525
Gly Ala Val Met Glu Gly Gln Leu Asn Gln Asp Asp Ser Ile Leu Lys
530 535 540
Val Ala Val Lys Thr Met Lys Ile Ala Ile Cys Thr Arg Ser Glu Leu
545 550 555 560
Glu Asp Phe Leu Ser Glu Ala Val Cys Met Lys Glu Phe Asp His Pro
565 570 575
Asn Val Met Arg Leu Ile Gly Val Cys Phe Gln Gly Ser Glu Arg Glu
580 585 590
Ser Phe Pro Ala Pro Val Val Ile Leu Pro Phe Met Lys His Gly Asp
595 600 605
Leu His Ser Phe Leu Leu Tyr Ser Arg Leu Gly Asp Gln Pro Val Tyr
610 615 620
Leu Pro Thr Gln Met Leu Val Lys Phe Met Ala Asp Ile Ala Ser Gly
625 630 635 640
Met Glu Tyr Leu Ser Thr Lys Arg Phe Ile His Arg Asp Leu Ala Ala
645 650 655
Arg Asn Cys Met Leu Asn Glu Asn Met Ser Val Cys Val Ala Asp Phe
660 665 670
Gly Leu Ser Lys Lys Ile Tyr Asn Gly Asp Tyr Tyr Arg Gln Gly Arg
675 680 685
Ile Ala Lys Met Pro Val Lys Trp Ile Ala Ile Glu Ser Leu Ala Asp
690 695 700
Arg Val Tyr Thr Ser Lys Ser Asp Val Trp Ser Phe Gly Val Thr Met
705 710 715 720
Trp Glu Ile Ala Thr Arg Gly Gln Thr Pro Tyr Pro Gly Val Glu Asn
725 730 735
Ser Glu Ile Tyr Asp Tyr Leu Arg Gln Gly Asn Arg Leu Lys Gln Pro
740 745 750
Ala Asp Cys Leu Asp Gly Leu Tyr Ala Leu Met Ser Arg Cys Trp Glu
755 760 765
Leu Asn Pro Gln Asp Arg Pro Ser Phe Thr Glu Leu Arg Glu Asp Leu
770 775 780
Glu Asn Thr Leu Lys Ala Leu Pro Pro Ala Gln Glu Pro Asp Glu Ile
785 790 795 800
Leu Tyr Val Asn Met Asp Glu Gly Gly Gly Tyr Pro Glu Pro Pro Gly
805 810 815
Ala Ala Gly Gly Ala Asp Pro Pro Thr Gln Pro Asp Pro Lys Asp Ser
820 825 830
Cys Ser Cys Leu Thr Ala Ala Glu Val His Pro Ala Gly Arg Tyr Val
835 840 845
Leu Cys Pro Ser Thr Thr Pro Ser Pro Ala Gln Pro
850 855 860
<210> 5
<211> 330
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Met Ser Thr Val His Glu Ile Leu Cys Lys Leu Ser Leu Glu Gly Asp
1 5 10 15
His Ser Thr Pro Pro Ser Ala Tyr Gly Ser Val Lys Ala Tyr Thr Asn
20 25 30
Phe Asp Ala Glu Arg Asp Ala Leu Asn Ile Glu Thr Ala Ile Lys Thr
35 40 45
Lys Gly Val Asp Glu Val Thr Ile Val Asn Ile Leu Thr Asn Arg Ser
50 55 60
Asn Ala Gln Arg Gln Asp Ile Ala Phe Ala Tyr Gln Arg Arg Thr Lys
65 70 75 80
Lys Glu Leu Ala Ser Ala Leu Lys Ser Ala Leu Ser Gly His Leu Glu
85 90 95
Thr Leu Ile Leu Gly Leu Leu Lys Thr Pro Ala Gln Tyr Asp Ala Ser
100 105 110
Glu Leu Lys Ala Ser Met Lys Gly Leu Gly Thr Asp Glu Asp Ser Leu
115 120 125
Ile Glu Ile Ile Cys Ser Arg Thr Asn Gln Glu Leu Gln Glu Ile Asn
130 135 140
Arg Val Tyr Lys Glu Met Tyr Lys Thr Asp Leu Glu Lys Asp Ile Ile
145 150 155 160
Ser Asp Thr Ser Gly Asp Phe Arg Lys Leu Met Val Ala Leu Ala Lys
165 170 175
Gly Arg Arg Ala Glu Asp Gly Ser Val Ile Asp Tyr Glu Leu Ile Asp
180 185 190
Gln Asp Ala Arg Asp Leu Tyr Asp Ala Gly Val Lys Arg Lys Gly Thr
195 200 205
Asp Val Pro Lys Trp Ile Ser Ile Met Thr Glu Arg Ser Val Pro His
210 215 220
Leu Gln Lys Val Phe Asp Arg Tyr Lys Ser Tyr Ser Pro Tyr Asp Met
225 230 235 240
Leu Glu Ser Ile Arg Lys Glu Val Lys Gly Asp Leu Glu Asn Ala Phe
245 250 255
Leu Asn Leu Val Gln Cys Ile Gln Asn Lys Pro Leu Tyr Phe Ala Asp
260 265 270
Arg Leu Tyr Asp Ser Met Lys Gly Lys Gly Thr Arg Asp Lys Val Leu
275 280 285
Ile Arg Ile Met Val Ser Arg Ser Glu Val Asp Met Leu Lys Ile Arg
290 295 300
Ser Glu Phe Lys Arg Lys Tyr Gly Lys Ser Leu Tyr Tyr Tyr Ile Gln
305 310 315 320
Gln Asp Thr Lys Gly Asp Tyr Gln Lys Ala
325 330
<210> 6
<211> 210
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Met Gly Lys Gly Asp Pro Lys Lys Pro Arg Gly Lys Met Ser Ser Tyr
1 5 10 15
Ala Phe Phe Val Gln Thr Cys Arg Glu Glu His Lys Lys Lys His Pro
20 25 30
Asp Ala Ser Val Asn Phe Ser Glu Phe Ser Lys Lys Cys Ser Glu Arg
35 40 45
Trp Lys Thr Met Ser Ala Lys Glu Lys Gly Lys Phe Glu Asp Met Ala
50 55 60
Lys Ala Asp Lys Ala Arg Tyr Glu Arg Glu Met Lys Thr Tyr Ile Pro
65 70 75 80
Pro Lys Gly Glu Thr Lys Lys Lys Phe Lys Asp Pro Asn Ala Pro Lys
85 90 95
Arg Pro Pro Ser Ala Phe Phe Leu Phe Cys Ser Glu Tyr Arg Pro Lys
100 105 110
Ile Lys Gly Glu His Pro Gly Leu Ser Ile Gly Asp Val Ala Lys Lys
115 120 125
Leu Gly Glu Met Trp Asn Asn Thr Ala Ala Asp Asp Lys Gln Pro Tyr
130 135 140
Glu Lys Lys Ala Ala Lys Leu Lys Glu Lys Tyr Glu Lys Asp Ile Ala
145 150 155 160
Ala Tyr Arg Ala Lys Gly Lys Pro Asp Ala Ala Lys Lys Gly Val Val
165 170 175
Lys Ala Glu Lys Ser Lys Lys Lys Lys Glu Glu Glu Glu Asp Glu Glu
180 185 190
Asp Glu Glu Asp Glu Glu Glu Glu Glu Asp Glu Glu Asp Glu Asp Glu
195 200 205
Glu Glu
210
<210> 7
<211> 580
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Met Ala Glu Asp Asp Pro Tyr Leu Gly Arg Pro Glu Gln Met Phe His
1 5 10 15
Leu Asp Pro Ser Leu Thr His Thr Ile Phe Asn Pro Glu Val Phe Gln
20 25 30
Pro Gln Met Ala Leu Pro Thr Asp Gly Pro Tyr Leu Gln Ile Leu Glu
35 40 45
Gln Pro Lys Gln Arg Gly Phe Arg Phe Arg Tyr Val Cys Glu Gly Pro
50 55 60
Ser His Gly Gly Leu Pro Gly Ala Ser Ser Glu Lys Asn Lys Lys Ser
65 70 75 80
Tyr Pro Gln Val Lys Ile Cys Asn Tyr Val Gly Pro Ala Lys Val Ile
85 90 95
Val Gln Leu Val Thr Asn Gly Lys Asn Ile His Leu His Ala His Ser
100 105 110
Leu Val Gly Lys His Cys Glu Asp Gly Ile Cys Thr Val Thr Ala Gly
115 120 125
Pro Lys Asp Met Val Val Gly Phe Ala Asn Leu Gly Ile Leu His Val
130 135 140
Thr Lys Lys Lys Val Phe Glu Thr Leu Glu Ala Arg Met Thr Glu Ala
145 150 155 160
Cys Ile Arg Gly Tyr Asn Pro Gly Leu Leu Val His Pro Asp Leu Ala
165 170 175
Tyr Leu Gln Ala Glu Gly Gly Gly Asp Arg Gln Leu Gly Asp Arg Glu
180 185 190
Lys Glu Leu Ile Arg Gln Ala Ala Leu Gln Gln Thr Lys Glu Met Asp
195 200 205
Leu Ser Val Val Arg Leu Met Phe Thr Ala Phe Leu Pro Asp Ser Thr
210 215 220
Gly Ser Phe Thr Arg Arg Leu Glu Pro Val Val Ser Asp Ala Ile Tyr
225 230 235 240
Asp Ser Ser Glu Ala Pro Asn Ala Ser Asn Leu Lys Ile Val Arg Met
245 250 255
Asp Arg Thr Ala Gly Cys Val Thr Gly Gly Glu Glu Ile Tyr Leu Leu
260 265 270
Cys Asp Lys Val Gln Lys Asp Asp Ile Gln Ile Arg Phe Tyr Glu Glu
275 280 285
Glu Glu Asn Gly Gly Val Trp Glu Gly Phe Gly Asp Phe Ser Pro Thr
290 295 300
Asp Val His Arg Gln Phe Ala Ile Val Phe Lys Thr Pro Lys Tyr Lys
305 310 315 320
Asp Ile Asn Ile Thr Lys Pro Ala Ser Val Phe Val Gln Leu Arg Arg
325 330 335
Lys Ser Asp Leu Glu Thr Ser Glu Pro Lys Pro Phe Leu Tyr Tyr Pro
340 345 350
Glu Ile Lys Asp Lys Glu Glu Val Gln Arg Lys Arg Gln Lys Leu Met
355 360 365
Pro Asn Phe Ser Asp Ser Phe Gly Gly Gly Ser Gly Ala Gly Ala Gly
370 375 380
Gly Gly Gly Met Phe Gly Ser Gly Gly Gly Gly Gly Gly Thr Gly Ser
385 390 395 400
Thr Gly Pro Gly Tyr Ser Phe Pro His Tyr Gly Phe Pro Thr Tyr Gly
405 410 415
Gly Ile Thr Phe His Pro Gly Thr Thr Lys Ser Asn Ala Gly Met Lys
420 425 430
His Gly Thr Met Asp Thr Glu Ser Lys Lys Asp Pro Glu Gly Cys Asp
435 440 445
Lys Ser Asp Asp Lys Asn Thr Val Asn Leu Phe Gly Lys Val Ile Glu
450 455 460
Thr Thr Glu Gln Asp Gln Glu Pro Ser Glu Ala Thr Val Gly Asn Gly
465 470 475 480
Glu Val Thr Leu Thr Tyr Ala Thr Gly Thr Lys Glu Glu Ser Ala Gly
485 490 495
Val Gln Asp Asn Leu Phe Leu Glu Lys Ala Met Gln Leu Ala Lys Arg
500 505 510
His Ala Asn Ala Leu Phe Asp Tyr Ala Val Thr Gly Asp Val Lys Met
515 520 525
Leu Leu Ala Val Gln Arg His Leu Thr Ala Val Gln Asp Glu Asn Gly
530 535 540
Asp Ser Val Leu His Leu Ala Ser Ser His Leu His Ser Gln Leu Val
545 550 555 560
Arg Asp Leu Leu Glu Val Thr Ser Gly Leu Ile Ser Asp Asp Ile Ile
565 570 575
Asn Met Arg Asn
580
<210> 8
<211> 350
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Met Ala Ala Ala Ala Ala Ala Gly Ala Gly Pro Glu Met Val Arg Gly
1 5 10 15
Gln Val Phe Asp Val Gly Pro Arg Tyr Thr Asn Leu Ser Tyr Ile Gly
20 25 30
Glu Gly Ala Tyr Gly Met Val Cys Ser Ala Tyr Asp Asn Val Asn Lys
35 40 45
Val Arg Val Ala Ile Lys Lys Ile Ser Pro Phe Glu His Gln Thr Tyr
50 55 60
Cys Gln Arg Thr Leu Arg Glu Ile Lys Ile Leu Leu Arg Phe Arg His
65 70 75 80
Glu Asn Ile Ile Gly Ile Asn Asp Ile Ile Arg Ala Pro Thr Ile Glu
85 90 95
Gln Met Lys Asp Val Tyr Ile Val Gln Asp Leu Met Glu Thr Asp Leu
100 105 110
Tyr Lys Leu Leu Lys Thr Gln His Leu Ser Asn Asp His Ile Cys Tyr
115 120 125
Phe Leu Tyr Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser Ala Asn
130 135 140
Val Leu His Arg Asp Leu Lys Pro Ser Asn Leu Leu Leu Asn Thr Thr
145 150 155 160
Cys Asp Leu Lys Ile Cys Asp Phe Gly Leu Ala Arg Val Ala Asp Pro
165 170 175
Asp His Asp His Thr Gly Phe Leu Thr Glu Tyr Val Ala Thr Arg Trp
180 185 190
Tyr Arg Ala Pro Glu Ile Met Leu Asn Ser Lys Gly Tyr Thr Lys Ser
195 200 205
Ile Asp Ile Trp Ser Val Gly Cys Ile Leu Ala Glu Met Leu Ser Asn
210 215 220
Arg Pro Ile Phe Pro Gly Lys His Tyr Leu Asp Gln Leu Asn His Ile
225 230 235 240
Leu Gly Ile Leu Gly Ser Pro Ser Gln Glu Asp Leu Asn Cys Ile Ile
245 250 255
Asn Leu Lys Ala Arg Asn Tyr Leu Leu Ser Leu Pro His Lys Asn Lys
260 265 270
Val Pro Trp Asn Arg Leu Phe Pro Asn Ala Asp Ser Lys Ala Leu Asp
275 280 285
Leu Leu Asp Lys Met Leu Thr Phe Asn Pro His Lys Arg Ile Glu Val
290 295 300
Glu Gln Ala Leu Ala His Pro Tyr Leu Glu Gln Tyr Tyr Asp Pro Ser
305 310 315 320
Asp Glu Pro Ile Ala Glu Ala Pro Phe Lys Phe Asp Met Glu Leu Asp
325 330 335
Asp Leu Pro Lys Glu Lys Leu Lys Glu Leu Ile Phe Glu Glu
340 345 350
<210> 9
<211> 600
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Met Ser Thr Ala Ser Ala Ala Ser Ser Ser Ser Ser Ser Ser Ala Gly
1 5 10 15
Glu Met Ile Glu Ala Pro Ser Gln Val Leu Asn Phe Glu Glu Ile Asp
20 25 30
Tyr Lys Glu Ile Glu Val Glu Glu Val Val Gly Arg Gly Ala Phe Gly
35 40 45
Val Val Cys Lys Ala Lys Trp Arg Ala Lys Asp Val Ala Ile Lys Gln
50 55 60
Ile Glu Ser Glu Ser Glu Arg Lys Ala Phe Ile Val Glu Leu Arg Gln
65 70 75 80
Leu Ser Arg Val Asn His Pro Asn Ile Val Lys Leu Tyr Gly Ala Cys
85 90 95
Leu Asn Pro Val Cys Leu Val Met Glu Tyr Ala Glu Gly Gly Ser Leu
100 105 110
Tyr Asn Val Leu His Gly Ala Glu Pro Leu Pro Tyr Tyr Thr Ala Ala
115 120 125
His Ala Met Ser Trp Cys Leu Gln Cys Ser Gln Gly Val Ala Tyr Leu
130 135 140
His Ser Met Gln Pro Lys Ala Leu Ile His Arg Asp Leu Lys Pro Pro
145 150 155 160
Asn Leu Leu Leu Val Ala Gly Gly Thr Val Leu Lys Ile Cys Asp Phe
165 170 175
Gly Thr Ala Cys Asp Ile Gln Thr His Met Thr Asn Asn Lys Gly Ser
180 185 190
Ala Ala Trp Met Ala Pro Glu Val Phe Glu Gly Ser Asn Tyr Ser Glu
195 200 205
Lys Cys Asp Val Phe Ser Trp Gly Ile Ile Leu Trp Glu Val Ile Thr
210 215 220
Arg Arg Lys Pro Phe Asp Glu Ile Gly Gly Pro Ala Phe Arg Ile Met
225 230 235 240
Trp Ala Val His Asn Gly Thr Arg Pro Pro Leu Ile Lys Asn Leu Pro
245 250 255
Lys Pro Ile Glu Ser Leu Met Thr Arg Cys Trp Ser Lys Asp Pro Ser
260 265 270
Gln Arg Pro Ser Met Glu Glu Ile Val Lys Ile Met Thr His Leu Met
275 280 285
Arg Tyr Phe Pro Gly Ala Asp Glu Pro Leu Gln Tyr Pro Cys Gln Tyr
290 295 300
Ser Asp Glu Gly Gln Ser Asn Ser Ala Thr Ser Thr Gly Ser Phe Met
305 310 315 320
Asp Ile Ala Ser Thr Asn Thr Ser Asn Lys Ser Asp Thr Asn Met Glu
325 330 335
Gln Val Pro Ala Thr Asn Asp Thr Ile Lys Arg Leu Glu Ser Lys Leu
340 345 350
Leu Lys Asn Gln Ala Lys Gln Gln Ser Glu Ser Gly Arg Leu Ser Leu
355 360 365
Gly Ala Ser Arg Gly Ser Ser Val Glu Ser Leu Pro Pro Thr Ser Glu
370 375 380
Gly Lys Arg Met Ser Ala Asp Met Ser Glu Ile Glu Ala Arg Ile Ala
385 390 395 400
Ala Thr Thr Ala Tyr Ser Lys Pro Lys Arg Gly His Arg Lys Thr Ala
405 410 415
Ser Phe Gly Asn Ile Leu Asp Val Pro Glu Ile Val Ile Ser Gly Asn
420 425 430
Gly Gln Pro Arg Arg Arg Ser Ile Gln Asp Leu Thr Val Thr Gly Thr
435 440 445
Glu Pro Gly Gln Val Ser Ser Arg Ser Ser Ser Pro Ser Val Arg Met
450 455 460
Ile Thr Thr Ser Gly Pro Thr Ser Glu Lys Pro Thr Arg Ser His Pro
465 470 475 480
Trp Thr Pro Asp Asp Ser Thr Asp Thr Asn Gly Ser Asp Asn Ser Ile
485 490 495
Pro Met Ala Tyr Leu Thr Leu Asp His Gln Leu Gln Pro Leu Ala Pro
500 505 510
Cys Pro Asn Ser Lys Glu Ser Met Ala Val Phe Glu Gln His Cys Lys
515 520 525
Met Ala Gln Glu Tyr Met Lys Val Gln Thr Glu Ile Ala Leu Leu Leu
530 535 540
Gln Arg Lys Gln Glu Leu Val Ala Glu Leu Asp Gln Asp Glu Lys Asp
545 550 555 560
Gln Gln Asn Thr Ser Arg Leu Val Gln Glu His Lys Lys Leu Leu Asp
565 570 575
Glu Asn Lys Ser Leu Ser Thr Tyr Tyr Gln Gln Cys Lys Lys Gln Leu
580 585 590
Glu Val Ile Arg Ser Gln Gln Gln
595 600
<210> 10
<211> 419
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Met Ser Asp Asn Gly Pro Gln Asn Gln Arg Asn Ala Pro Arg Ile Thr
1 5 10 15
Phe Gly Gly Pro Ser Asp Ser Thr Gly Ser Asn Gln Asn Gly Glu Arg
20 25 30
Ser Gly Ala Arg Ser Lys Gln Arg Arg Pro Gln Gly Leu Pro Asn Asn
35 40 45
Thr Ala Ser Trp Phe Thr Ala Leu Thr Gln His Gly Lys Glu Asp Leu
50 55 60
Lys Phe Pro Arg Gly Gln Gly Val Pro Ile Asn Thr Asn Ser Ser Pro
65 70 75 80
Asp Asp Gln Ile Gly Tyr Tyr Arg Arg Ala Thr Arg Arg Ile Arg Gly
85 90 95
Gly Asp Gly Lys Met Lys Asp Leu Ser Pro Arg Trp Tyr Phe Tyr Tyr
100 105 110
Leu Gly Thr Gly Pro Glu Ala Gly Leu Pro Tyr Gly Ala Asn Lys Asp
115 120 125
Gly Ile Ile Trp Val Ala Thr Glu Gly Ala Leu Asn Thr Pro Lys Asp
130 135 140
His Ile Gly Thr Arg Asn Pro Ala Asn Asn Ala Ala Ile Val Leu Gln
145 150 155 160
Leu Pro Gln Gly Thr Thr Leu Pro Lys Gly Phe Tyr Ala Glu Gly Ser
165 170 175
Arg Gly Gly Ser Gln Ala Ser Ser Arg Ser Ser Ser Arg Ser Arg Asn
180 185 190
Ser Ser Arg Asn Ser Thr Pro Gly Ser Ser Arg Gly Thr Ser Pro Ala
195 200 205
Arg Met Ala Gly Asn Gly Gly Asp Ala Ala Leu Ala Leu Leu Leu Leu
210 215 220
Asp Arg Leu Asn Gln Leu Glu Ser Lys Met Ser Gly Lys Gly Gln Gln
225 230 235 240
Gln Gln Gly Gln Thr Val Thr Lys Lys Ser Ala Ala Glu Ala Ser Lys
245 250 255
Lys Pro Arg Gln Lys Arg Thr Ala Thr Lys Ala Tyr Asn Val Thr Gln
260 265 270
Ala Phe Gly Arg Arg Gly Pro Glu Gln Thr Gln Gly Asn Phe Gly Asp
275 280 285
Gln Glu Leu Ile Arg Gln Gly Thr Asp Tyr Lys His Trp Pro Gln Ile
290 295 300
Ala Gln Phe Ala Pro Ser Ala Ser Ala Phe Phe Gly Met Ser Arg Ile
305 310 315 320
Gly Met Glu Val Thr Pro Ser Gly Thr Trp Leu Thr Tyr Thr Gly Ala
325 330 335
Ile Lys Leu Asp Asp Lys Asp Pro Asn Phe Lys Asp Gln Val Ile Leu
340 345 350
Leu Asn Lys His Ile Asp Ala Tyr Lys Thr Phe Pro Pro Thr Glu Pro
355 360 365
Lys Lys Asp Lys Lys Lys Lys Ala Asp Glu Thr Gln Ala Leu Pro Gln
370 375 380
Arg Gln Lys Lys Gln Gln Thr Val Thr Leu Leu Pro Ala Ala Asp Leu
385 390 395 400
Asp Asp Phe Ser Lys Gln Leu Gln Gln Ser Met Ser Ser Ala Asp Ser
405 410 415
Thr Gln Ala
<210> 11
<211> 630
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Ala Tyr Thr Arg Tyr Val Asp Asn Asn Phe Cys Gly Pro Asp Gly Tyr
1 5 10 15
Pro Leu Glu Cys Ile Lys Asp Leu Leu Ala Arg Ala Gly Lys Ala Ser
20 25 30
Cys Thr Leu Ser Glu Gln Leu Asp Phe Ile Asp Thr Lys Arg Gly Val
35 40 45
Tyr Cys Cys Arg Glu His Glu His Glu Ile Ala Trp Tyr Thr Glu Arg
50 55 60
Ser Glu Lys Ser Tyr Glu Leu Gln Thr Pro Phe Glu Ile Lys Leu Ala
65 70 75 80
Lys Lys Phe Asp Thr Phe Asn Gly Glu Cys Pro Asn Phe Val Phe Pro
85 90 95
Leu Asn Ser Ile Ile Lys Thr Ile Gln Pro Arg Val Glu Lys Lys Lys
100 105 110
Leu Asp Gly Phe Met Gly Arg Ile Arg Ser Val Tyr Pro Val Ala Ser
115 120 125
Pro Asn Glu Cys Asn Gln Met Cys Leu Ser Thr Leu Met Lys Cys Asp
130 135 140
His Cys Gly Glu Thr Ser Trp Gln Thr Gly Asp Phe Val Lys Ala Thr
145 150 155 160
Cys Glu Phe Cys Gly Thr Glu Asn Leu Thr Lys Glu Gly Ala Thr Thr
165 170 175
Cys Gly Tyr Leu Pro Gln Asn Ala Val Val Lys Ile Tyr Cys Pro Ala
180 185 190
Cys His Asn Ser Glu Val Gly Pro Glu His Ser Leu Ala Glu Tyr His
195 200 205
Asn Glu Ser Gly Leu Lys Thr Ile Leu Arg Lys Gly Gly Arg Thr Ile
210 215 220
Ala Phe Gly Gly Cys Val Phe Ser Tyr Val Gly Cys His Asn Lys Cys
225 230 235 240
Ala Tyr Trp Val Pro Arg Ala Ser Ala Asn Ile Gly Cys Asn His Thr
245 250 255
Gly Val Val Gly Glu Gly Ser Glu Gly Leu Asn Asp Asn Leu Leu Glu
260 265 270
Ile Leu Gln Lys Glu Lys Val Asn Ile Asn Ile Val Gly Asp Phe Lys
275 280 285
Leu Asn Glu Glu Ile Ala Ile Ile Leu Ala Ser Phe Ser Ala Ser Thr
290 295 300
Ser Ala Phe Val Glu Thr Val Lys Gly Leu Asp Tyr Lys Ala Phe Lys
305 310 315 320
Gln Ile Val Glu Ser Cys Gly Asn Phe Lys Val Thr Lys Gly Lys Ala
325 330 335
Lys Lys Gly Ala Trp Asn Ile Gly Glu Gln Lys Ser Ile Leu Ser Pro
340 345 350
Leu Tyr Ala Phe Ala Ser Glu Ala Ala Arg Val Val Arg Ser Ile Phe
355 360 365
Ser Arg Thr Leu Glu Thr Ala Gln Asn Ser Val Arg Val Leu Gln Lys
370 375 380
Ala Ala Ile Thr Ile Leu Asp Gly Ile Ser Gln Tyr Ser Leu Arg Leu
385 390 395 400
Ile Asp Ala Met Met Phe Thr Ser Asp Leu Ala Thr Asn Asn Leu Val
405 410 415
Val Met Ala Tyr Ile Thr Gly Gly Val Val Gln Leu Thr Ser Gln Trp
420 425 430
Leu Thr Asn Ile Phe Gly Thr Val Tyr Glu Lys Leu Lys Pro Val Leu
435 440 445
Asp Trp Leu Glu Glu Lys Phe Lys Glu Gly Val Glu Phe Leu Arg Asp
450 455 460
Gly Trp Glu Ile Val Lys Phe Ile Ser Thr Cys Ala Cys Glu Ile Val
465 470 475 480
Gly Gly Gln Ile Val Thr Cys Ala Lys Glu Ile Lys Glu Ser Val Gln
485 490 495
Thr Phe Phe Lys Leu Val Asn Lys Phe Leu Ala Leu Cys Ala Asp Ser
500 505 510
Ile Ile Ile Gly Gly Ala Lys Leu Lys Ala Leu Asn Leu Gly Glu Thr
515 520 525
Phe Val Thr His Ser Lys Gly Leu Tyr Arg Lys Cys Val Lys Ser Arg
530 535 540
Glu Glu Thr Gly Leu Leu Met Pro Leu Lys Ala Pro Lys Glu Ile Ile
545 550 555 560
Phe Leu Glu Gly Glu Thr Leu Pro Thr Glu Val Leu Thr Glu Glu Val
565 570 575
Val Leu Lys Thr Gly Asp Leu Gln Pro Leu Glu Gln Pro Thr Ser Glu
580 585 590
Ala Val Glu Ala Pro Leu Val Gly Thr Pro Val Cys Ile Asn Gly Leu
595 600 605
Met Leu Leu Glu Ile Lys Asp Thr Glu Lys Tyr Cys Ala Leu Ala Pro
610 615 620
Asn Met Met Val Thr Asn
625 630
<210> 12
<211> 306
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Ser Gly Phe Arg Lys Met Ala Phe Pro Ser Gly Lys Val Glu Gly Cys
1 5 10 15
Met Val Gln Val Thr Cys Gly Thr Thr Thr Leu Asn Gly Leu Trp Leu
20 25 30
Asp Asp Val Val Tyr Cys Pro Arg His Val Ile Cys Thr Ser Glu Asp
35 40 45
Met Leu Asn Pro Asn Tyr Glu Asp Leu Leu Ile Arg Lys Ser Asn His
50 55 60
Asn Phe Leu Val Gln Ala Gly Asn Val Gln Leu Arg Val Ile Gly His
65 70 75 80
Ser Met Gln Asn Cys Val Leu Lys Leu Lys Val Asp Thr Ala Asn Pro
85 90 95
Lys Thr Pro Lys Tyr Lys Phe Val Arg Ile Gln Pro Gly Gln Thr Phe
100 105 110
Ser Val Leu Ala Cys Tyr Asn Gly Ser Pro Ser Gly Val Tyr Gln Cys
115 120 125
Ala Met Arg Pro Asn Phe Thr Ile Lys Gly Ser Phe Leu Asn Gly Ser
130 135 140
Cys Gly Ser Val Gly Phe Asn Ile Asp Tyr Asp Cys Val Ser Phe Cys
145 150 155 160
Tyr Met His His Met Glu Leu Pro Thr Gly Val His Ala Gly Thr Asp
165 170 175
Leu Glu Gly Asn Phe Tyr Gly Pro Phe Val Asp Arg Gln Thr Ala Gln
180 185 190
Ala Ala Gly Thr Asp Thr Thr Ile Thr Val Asn Val Leu Ala Trp Leu
195 200 205
Tyr Ala Ala Val Ile Asn Gly Asp Arg Trp Phe Leu Asn Arg Phe Thr
210 215 220
Thr Thr Leu Asn Asp Phe Asn Leu Val Ala Met Lys Tyr Asn Tyr Glu
225 230 235 240
Pro Leu Thr Gln Asp His Val Asp Ile Leu Gly Pro Leu Ser Ala Gln
245 250 255
Thr Gly Ile Ala Val Leu Asp Met Cys Ala Ser Leu Lys Glu Leu Leu
260 265 270
Gln Asn Gly Met Asn Gly Arg Thr Ile Leu Gly Ser Ala Leu Leu Glu
275 280 285
Asp Glu Phe Thr Pro Phe Asp Val Val Arg Gln Cys Ser Gly Val Thr
290 295 300
Phe Gln
305

Claims (10)

1.一种蛋白质热稳定性检测芯片,用于抗新冠药物的筛选,同时也可用于中药等靶点筛选,其特征在于,所述的蛋白质芯片中包括新冠病毒相关药物靶点蛋白的纯品;所述的靶点蛋白的保存液为含有10-30%甘油,pH=6.7-7.5的磷酸盐缓冲液,所述的保存液中还包括防腐剂和信号增强剂;所述的热稳定性荧光信号信号增强剂为0.001-0.1%叠氮化钠。
2.根据权利要求1所述的蛋白质热稳定性检测芯片,其特征在于,所述的靶点蛋白包括经过网络药理学筛选相关的高频药物靶点,包含宿主来源和病毒来源两部分;所述的靶点蛋白包括:重组人蛋白ACE2、Cathepsin B(CTSB)、CD147、AXL、Anneixn A2、HMGB1、NFκB1(P50)、MAPK1、TAB1、重组病毒SARS-CoV-2Nucleocapsid Protein、Non-structuralprotein SARS-CoV-2NSP2、SARS-CoV-23C-like Proteinase。
3.根据权利要求2所述的蛋白质热稳定性检测芯片,其特征在于,所述的靶点蛋白用于热稳定性检测的序列进一步优化为SEQ ID NO.1-12。
4.根据权利要求3所述的蛋白质热稳定性检测芯片,其特征在于,所述的芯片中用于热稳定性检测的NFκB1(P50)蛋白终浓度为0.045-1μg/μL。
5.根据权利要求4所述的蛋白质热稳定性检测芯片,其特征在于,所述的ACE2、Cathepsin B(CTSB)、CD147、AXL、Anneixn A2、HMGB1、NFκB1(P50)、MAPK1、TAB1、重组病毒SARS-CoV-2Nucleocapsid Protein、Non-structural protein SARS-CoV-2NSP2、SARS-CoV-2 3C-like Proteinase的用于热稳定性检测时终浓度分别为0.045-1μg/μL。
6.根据权利要求2所述的蛋白质热稳定性检测芯片,其特征在于所述的靶点蛋白用于热稳定性检测时的纯度为90%及以上。
7.根据权利要求2所述的蛋白质热稳定性检测芯片,其特征在于其制备方法采用聚丙烯塑料多孔反应板,每孔放置2倍蛋白工作浓度的蛋白靶点于保存液中,4℃保存。
8.一种试剂盒,其特征在于,包括权利要求1-7任一项所述的蛋白质热稳定性检测芯片。
9.根据权利要求8所述的试剂盒,其特征在于,所述的试剂盒中还包括样品稀释液和信号增强剂,所述的样品稀释液为含有10-30%甘油、pH=6.7-7.5的0.01M磷酸盐缓冲液,所述的信号增强剂为0.01%的叠氮化钠。
10.根据权利要求8所述的试剂盒,其特征在于,可用于有效中药复杂成分的抗新冠病毒作用靶点的直接筛选,其检测方法特征在于中药混合物复杂成分无需标记和分离,中药复杂成分检测经超滤去除蛋白,以靶点蛋白的热稳定性Tm数值变化判断是否为中药的靶点。
CN202210056150.9A 2022-01-18 2022-01-18 一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒 Active CN114606345B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210056150.9A CN114606345B (zh) 2022-01-18 2022-01-18 一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210056150.9A CN114606345B (zh) 2022-01-18 2022-01-18 一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒

Publications (2)

Publication Number Publication Date
CN114606345A true CN114606345A (zh) 2022-06-10
CN114606345B CN114606345B (zh) 2024-02-27

Family

ID=81857999

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210056150.9A Active CN114606345B (zh) 2022-01-18 2022-01-18 一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒

Country Status (1)

Country Link
CN (1) CN114606345B (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103645324A (zh) * 2013-12-03 2014-03-19 胡朝阳 基于细胞热转移技术的高通量药物靶点筛选方法
CN112630444A (zh) * 2020-12-11 2021-04-09 珠海碳云智能科技有限公司 基于靶点蛋白的多肽筛选方法
CN112750496A (zh) * 2020-12-29 2021-05-04 大连理工大学 一种covid-19棘突状蛋白的小分子抑制剂的筛选方法、其筛选的活性分子及用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103645324A (zh) * 2013-12-03 2014-03-19 胡朝阳 基于细胞热转移技术的高通量药物靶点筛选方法
CN112630444A (zh) * 2020-12-11 2021-04-09 珠海碳云智能科技有限公司 基于靶点蛋白的多肽筛选方法
CN112750496A (zh) * 2020-12-29 2021-05-04 大连理工大学 一种covid-19棘突状蛋白的小分子抑制剂的筛选方法、其筛选的活性分子及用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PANTOLIANO MW等: "High-density miniaturized thermal shift assays as a general strategy for drug discovery", J BIOMOL SCREEN, pages 429 - 440 *
刘艾林等: "基于靶点的抗新型冠状病毒病COVID-19药物发现", 药学学报, vol. 55, no. 06, pages 1073 - 1080 *

Also Published As

Publication number Publication date
CN114606345B (zh) 2024-02-27

Similar Documents

Publication Publication Date Title
CN110628955B (zh) 一种用于检测埃博拉病毒的crRNA靶点及CRISPR-Cas13a系统
Hartman et al. Katanin, a microtubule-severing protein, is a novel AAA ATPase that targets to the centrosome using a WD40-containing subunit
CN109991409B (zh) 胃蛋白酶原i/胃蛋白酶原ii检测试剂盒
CN105441595B (zh) 一种用于检测hbv-b/c的数字pcr绝对定量分型检测试剂盒
CN105506078B (zh) 一种用于平行测定尿嘧啶-dna糖基化酶和内切酶iv活性的方法及其应用和试剂盒
CN104131112B (zh) 一种淋球菌检测用引物组、含有该引物组的试剂盒及其应用
CN105044257A (zh) 无血培养的脓毒症质谱诊断
CN105838777A (zh) ddPCR技术监测肺癌患者对酪氨酸激酶抑制剂继发耐药的方法
CN111647054A (zh) 一种用于检测新型冠状病毒SARS-CoV-2抗体的试剂及其应用
CN103443627B (zh) 牙周病原菌血浆或血清抗体效价检测试剂盒
CN111088404B (zh) 一种快速检测柯萨奇病毒a16型、肠道病毒71型的rda方法及试剂盒
CN114134253A (zh) 鉴别非洲猪瘟野毒株和基因缺失株的荧光定量检测引物及试剂盒
CN106191286A (zh) 布鲁氏菌的检测方法、试剂盒及其应用
CN108624713A (zh) 一种猪伪狂犬病疫苗毒与野毒鉴别检测的方法及试剂盒
CN113368241A (zh) 一种冠状病毒主蛋白酶3CLpro抑制剂及其应用
CN114606345A (zh) 一种蛋白质热稳定性检测芯片的制备方法、检测方法和试剂盒
CN109851675B (zh) 一种口蹄疫诊断试剂盒及其所用口蹄疫诊断抗原
CN101995460B (zh) 莱克多巴胺残留的时间分辨免疫分析检测试剂盒及其检测方法
CN111537725A (zh) 高效定量检测细胞外囊泡中pd-1水平的方法、elisa试剂盒及使用方法
CN111007240A (zh) 一种基于crispr技术的均相酶免疫检验系统及其方法和应用
KR100671825B1 (ko) 인유두종바이러스에 의한 자궁경부암 진단키트
CN112210624B (zh) 一种高效三联检测中华鳖三种病原的lamp引物及试剂盒
CN103184264B (zh) 从红果小檗粗提物中筛选出的1型艾滋病病毒蛋白酶抑制剂及其应用
CN113444729A (zh) 一种幽门螺杆菌特异结合核酸适体及其应用
CN1231763C (zh) 艾滋病病毒快速检测试纸的制备及使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant